Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Amgen Heart Study Shows Positive Ivabradine Results

September 15, 2014 3:18 pm | News | Comments

Amgen announced data from the Phase 3 SHIFT study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. Read more...   

TOPICS:

Avanir Drug for Alzheimer's Agitation Excels in Trial

September 15, 2014 3:07 pm | News | Comments

Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients. Read more...                

TOPICS:

EMD Serono Announces 2014 GMSI Grant Winners

September 15, 2014 11:29 am | News | Comments

EMD Serono announced the recipients of the second annual Grant for Multiple Sclerosis Innovation at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS). Read more...

TOPICS:
Advertisement

Akashi Acquires Global Rights to Novel DMD Treatment

September 15, 2014 11:16 am | News | Comments

Akashi Therapeutics Inc. announced that it has acquired global rights to GsMTx-4, a peptide developed to address calcium level imbalance in muscle, a critical issue in Duchenne muscular dystrophy contributing to loss of function and other associated pathologies. Read more...

TOPICS:

Germany's Merck Discontinues Lung Cancer Drug Program

September 15, 2014 11:01 am | News | Comments

Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Read more...   

TOPICS:

Cardio3 BioSciences to Continue Phase 3 Heart Therapy Trial

September 15, 2014 10:53 am | News | Comments

Cardio3 BioSciences SA (C3BS) announced it has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol. Read more...            

TOPICS:

NIH Awards Aim to Improve Understanding of Cell Pathways

September 15, 2014 10:33 am | News | Comments

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses. Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies. Read more...

TOPICS:

Gilead to License Generic Version of Sovaldi

September 15, 2014 8:41 am | by The Associated Press | News | Comments

Gilead Sciences has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries. Read more...                 

TOPICS:
Advertisement

Researchers Find Defense Mechanism Against Viruses

September 12, 2014 2:00 pm | News | Comments

Researchers have discovered that a known quality control mechanism in human, animal and plant cells is active against viruses. They think it might represent one of the oldest defense mechanisms against viruses in evolutionary history.

TOPICS:

BioTime, Charity Partner for Trial of Vaccine for Lung Cancer

September 12, 2014 2:00 pm | News | Comments

BioTime, Inc. announced that its subsidiary Asterias Biotherapeutics, Inc. has reached an agreement with Cancer Research UK and Cancer Research Technology— the charity’s development and commercialization arm— to conduct a clinical trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer.

TOPICS:

Novartis, Penn Team for Cellular Therapeutics Center

September 12, 2014 2:00 pm | News | Comments

The Univ. of Pennsylvania has reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics on the Penn Medicine campus in Philadelphia.

TOPICS:

FDA Backs Injection for Obesity

September 12, 2014 2:00 pm | News | Comments

Federal health experts say Novo Nordisk's diabetes drug Victoza should be approved for a new use in treating obesity. The panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh its risks for patients who are obese or dangerously overweight.

TOPICS:

Scientists Can Reset Human Stem Cells

September 12, 2014 2:00 pm | News | Comments

Scientists have successfully reset human pluripotent stem cells to the earliest developmental state– equivalent to cells found in an embryo before it implants in the womb (seven to nine days old). These pristine stem cells may mark the true starting point for human development, but have until now been impossible to replicate in the lab.

TOPICS:

Phase 2a Begins for Genocea's Pneumococcus Vaccine

September 12, 2014 7:00 am | News | Comments

Genocea Biosciences, Inc. announced the initiation of a Phase 2a trial for GEN-004, the company’s universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.

TOPICS:

Biogen Shows Positive Effects in Year Two of RMS Drug Trial

September 12, 2014 7:00 am | News | Comments

Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading